Precigen Secures Up to $125 Million Non-Dilutive Financing from Pharmakon Advisors to Boost PAPZIMEOS Commercialization Efforts

Reuters

2025/09/03

<a href="https://laohu8.com/S/PGEN">Precigen</a> Secures Up to $125 Million Non-Dilutive Financing from Pharmakon Advisors to Boost PAPZIMEOS Commercialization Efforts

Precigen Inc., a biopharmaceutical company focused on innovative precision medicines, has announced a new credit facility agreement with investment funds managed by Pharmakon Advisors, LP. The agreement provides Precigen with up to $125 million in non-dilutive financing, structured across two tranches. The first tranche of $100 million has been funded at closing, while a second tranche of $25 million can be accessed at Precigen's discretion through March 31, 2027, subject to certain conditions. This financing aims to bolster Precigen's balance sheet, facilitating the US commercialization of their novel immunotherapy, PAPZIMEOS, and supporting potential expansion into international markets. The credit facility carries a variable interest rate of 6.50% plus the three-month secured overnight financing rate $(SOFR)$, with a SOFR floor of 3.75%. Evercore and Davis Polk LLP served as Precigen's financial and legal advisors, respectively, while Akin advised Pharmakon Advisors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precigen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY62821) on September 03, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2564367484"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564367484\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564367484?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-03 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564367484","market":"us","top_or_hot":-1,"title":"Precigen Secures Up to $125 Million Non-Dilutive Financing from Pharmakon Advisors to Boost PAPZIMEOS Commercialization Efforts","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PGEN\">Precigen</a> Secures Up to $125 Million Non-Dilutive Financing from Pharmakon Advisors to Boost PAPZIMEOS Commercialization Efforts\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Precigen Inc., a biopharmaceutical company focused on innovative precision medicines, has announced a new credit facility agreement with investment funds managed by Pharmakon Advisors, LP. The agreement provides Precigen with up to $125 million in non-dilutive financing, structured across two tranches. The first tranche of $100 million has been funded at closing, while a second tranche of $25 million can be accessed at Precigen's discretion through March 31, 2027, subject to certain conditions. This financing aims to bolster Precigen's balance sheet, facilitating the US commercialization of their novel immunotherapy, PAPZIMEOS, and supporting potential expansion into international markets. The credit facility carries a variable interest rate of 6.50% plus the three-month secured overnight financing rate <a href=\"https://laohu8.com/S/SOFR\">$(SOFR)$</a>, with a SOFR floor of 3.75%. <a href=\"https://laohu8.com/S/EVR\">Evercore</a> and Davis Polk LLP served as Precigen's financial and legal advisors, respectively, while Akin advised Pharmakon Advisors.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precigen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY62821) on September 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Precigen Secures Up to $125 Million Non-Dilutive Financing from Pharmakon Advisors to Boost PAPZIMEOS Commercialization Efforts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrecigen Secures Up to $125 Million Non-Dilutive Financing from Pharmakon Advisors to Boost PAPZIMEOS Commercialization Efforts\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-03 19:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PGEN\">Precigen</a> Secures Up to $125 Million Non-Dilutive Financing from Pharmakon Advisors to Boost PAPZIMEOS Commercialization Efforts\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Precigen Inc., a biopharmaceutical company focused on innovative precision medicines, has announced a new credit facility agreement with investment funds managed by Pharmakon Advisors, LP. The agreement provides Precigen with up to $125 million in non-dilutive financing, structured across two tranches. The first tranche of $100 million has been funded at closing, while a second tranche of $25 million can be accessed at Precigen's discretion through March 31, 2027, subject to certain conditions. This financing aims to bolster Precigen's balance sheet, facilitating the US commercialization of their novel immunotherapy, PAPZIMEOS, and supporting potential expansion into international markets. The credit facility carries a variable interest rate of 6.50% plus the three-month secured overnight financing rate <a href=\"https://laohu8.com/S/SOFR\">$(SOFR)$</a>, with a SOFR floor of 3.75%. <a href=\"https://laohu8.com/S/EVR\">Evercore</a> and Davis Polk LLP served as Precigen's financial and legal advisors, respectively, while Akin advised Pharmakon Advisors.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precigen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY62821) on September 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4127","symbol_name":"投資銀行業與經紀業","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250903:nNDLJ32NK:1","article_id":"2564367484","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564367484","pubTimestamp":1756897308,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Precigen Secures Up to $125 Million Non-Dilutive Financing from Pharmakon Advisors to Boost PAPZIMEOS Commercialization Efforts. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precigen Inc. published the original content used to generate this news brief via PR Newswire  on September 03, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4127":"投资银行业与经纪业","BK4139":"生物科技","PGEN":"Precigen","EVR":"Evercore"},"translate_title":"Precigen从Pharmakon Advisors获得高达1.25亿美元的非稀释性融资，以推动PAPZIMEOS的商业化工作","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVR":0.9,"PGEN":0.9},"content_text":"Precigen Secures Up to $125 Million Non-Dilutive Financing from Pharmakon Advisors to Boost PAPZIMEOS Commercialization Efforts\n    \n\n        Precigen Inc., a biopharmaceutical company focused on innovative precision medicines, has announced a new credit facility agreement with investment funds managed by Pharmakon Advisors, LP. The agreement provides Precigen with up to $125 million in non-dilutive financing, structured across two tranches. The first tranche of $100 million has been funded at closing, while a second tranche of $25 million can be accessed at Precigen's discretion through March 31, 2027, subject to certain conditions. This financing aims to bolster Precigen's balance sheet, facilitating the US commercialization of their novel immunotherapy, PAPZIMEOS, and supporting potential expansion into international markets. The credit facility carries a variable interest rate of 6.50% plus the three-month secured overnight financing rate $(SOFR)$, with a SOFR floor of 3.75%. Evercore and Davis Polk LLP served as Precigen's financial and legal advisors, respectively, while Akin advised Pharmakon Advisors.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precigen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY62821) on September 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}